Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batoclimab in Graves' Ophthalmopathy
NCT03938545Phase 2Terminated
- Sponsor
- Immunovant, Inc.
- Start
- Jul 2019
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of batoclimab in Graves' ophthalmopathy (TED), sponsored by Immunovant, Inc.. Started Jul 2019; status: terminated.
02
Drugs
batoclimab
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT03938545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938545.